We chose VRC01 because this prototype CD4 receptor binding-site bnAb has been extensively tested in the clinic for its ability to suppress viremia in patients and prevent infection after administration as a recombinant monoclonal antibody14–16 (clinicaltrials.gov NCT02568215, NCT02716675). This evidence concerns the gene CD4 and infection.